Firm
The tie-up between Perkins Coie and Ashurst may generate some striking numbers, but independent IP firms need not worry yet, according to practitioners
Perkins Coie’s US patent prosecution strength could provide Ashurst with an opportunity to enter an untapped market in Australia, but it may not be easy
Mitesh Patel at Reed Smith outlines why the US Copyright Office and courts have so far dismissed AI authorship and how inventors can protect AI-generated works
Xia Zheng, founder of AFD China, discusses balancing legal work with BD, new approaches to complex challenges, and the dangers of ‘over-optimism’
Sponsored
Sponsored
-
Sponsored by Bird & BirdSeiko Hidaka of Bird & Bird and Kento Sumi, currently seconded to Bird & Bird, analyse a landmark decision in a standard-essential patent case and its implications for licensing practices and future litigation in Japan -
Sponsored by Wanhuida Intellectual PropertyJicheng Yang of Wanhuida Intellectual Property considers whether a notable Beijing Intellectual Property Court decision signals a change to assessing inventive step in polymorph patents in China
-
Sponsored by Hechanova GroupEditha R Hechanova, Brenda P Rivera, and Maricris V Faderugao of Hechanova Group examine new trademark and patent representative rules aimed at professionalising intellectual property services and aligning with global standards
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Parth Bajaj of RNA, Technology and IP Attorneys consider the potential impact of two US cases on Indian jurisprudence and what constitutes fair use of copyrighted material in training AI models
-
Sponsored by Tilleke & GibbinsThe measures represent a ‘strategic leap’ for Vietnam’s intellectual property landscape, say Thuy Thi Ngoc Huynh and Yen Thi Hai Pham of T&G Law Firm LLC (TGVN), the local associate firm of Tilleke & Gibbins
-
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law analyses a ruling that clarifies the scope of patent infringement, territoriality limits, and research exemptions in a cross-border dispute over Pfizer’s pneumococcal vaccine
![1200_17th_images_071812[1] 3.jpg](https://static.legalbenchmarkinggroup.com/dims4/default/46d4318/2147483647/strip/true/crop/3328x1872+0+174/resize/320x180!/quality/90/?url=https%3A%2F%2Fk4-prod-legal.s3.eu-west-1.amazonaws.com%2Fbrightspot%2Fae%2Fda%2F3bb43c034f46989edd34a5c00e5f%2F1200-17th-images-0718121-3.jpg)
